Valneva: Revenue Down 37% with a Net Loss of €32.1 Million in Q1 2026
Valneva has released its Q1 2026 results, showing a 37% decrease in revenue and a net loss of €32.1 million, compared to a €9.2 million loss in Q1 2025. Concurrently, the company has announced a reorganization plan aimed at reducing operational expenses by 25 to 35% and decreasing its global workforce by 10 to 15%, while maintaining a strengthened cash position of €105.3 million excluding April financing.
Decline in Revenue, Commercial Portfolio in Transition
Valneva recorded a revenue of €30.9 million in Q1 2026, down 37% from €49.2 million in Q1 2025. Product sales amounted to €30.5 million compared to €48.6 million a year earlier. This decline reflects three major factors: the planned discontinuation of third-party product distribution (down 97.6%), a shift in delivery schedules to the U.S. Department of Defense (DoD) for the Ixiaro vaccine, and a change of distributor in Germany for Dukoral in January 2026. Within the travel vaccine portfolio, Ixiaro/Jespect generated €20.2 million (compared to €27.5 million the previous year), Dukoral €8.6 million (compared to €12.3 million), and Ixchiq €1.6 million (compared to €3.0 million), the latter decrease reflecting the absence of sporadic sales related to chikungunya outbreaks recorded in Q1 2025.
Compressed Margins and Worsened Operational Loss
The net loss for the quarter reached €32.1 million, compared to €9.2 million in Q1 2025, marking a deterioration of 249%. This decline primarily stems from lower sales and exceptional effects at the cost of sales level (contract terminations, standard cost adjustments, inventory impairments). The gross margin on product sales (excluding Ixchiq) stood at 45.2% compared to 62.7% in Q1 2025. For Ixiaro alone, the margin fell to 50.8% from 72.6% in Q1 2025, hampered by higher production costs related to the transfer of production to the new Almeida facility in Scotland. The operational loss worsened to €23.7 million (Q1 2025: €6.0 million), while adjusted EBITDA came in at minus €18.2 million compared to minus €0.6 million in Q1 2025. However, non-direct production operational expenses decreased: commercial expenses at €7.0 million (vs. €10.4 million), general and administrative expenses at €8.2 million (vs. €9.0 million).
Reduction of Expenses and Consolidation of Cash Reserves
To secure its business model, Valneva launched a reorganization plan in April 2026 targeting a 10 to 15% reduction in its global workforce and a 25 to 35% decrease in operational expenses in 2026 compared to 2025. The company is focusing its resources on key strategic projects, including the Lyme disease vaccine in partnership with Pfizer. On the cash front, Valneva showed a remarkable improvement in its operational cash consumption: €0.3 million in Q1 2026 compared to €8.1 million in Q1 2025. The group's cash reserves stood at €105.3 million as of March 31, 2026 (versus €109.7 million on December 31, 2025), with an additional €37.0 million from a fundraising event in April 2026. For 2026, Valneva has revised its product sales outlook downwards, now expected to be between €135 and €150 million (versus €145 to €160 million previously), reflecting an unfavorable trend in the adoption of travel vaccines due to geopolitical factors. Total revenue is revised between €145 and €160 million, with other revenues confirmed. The company anticipates a normalization of gross margins once the exceptional effects of Q1 2026 are absorbed.
